Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4943834 | 0.82 | HTT (0.61) | GABRA1GABRB2HTTALDH1A1HPGD | |
| SCHEMBL8465492 | 0.82 | HTT (0.61) | GABRA1GABRB2HTTALDH1A1HPGD | |
| SCHEMBL9550443 | 0.81 | HTT (0.60) | GABRA1GABRB2HTTALDH1A1HPGD | |
| SCHEMBL4247285 | 0.79 | HTT (0.58) | GABRA1GABRB2HTTALDH1A1HPGD | |
| SCHEMBL1092424 | 0.79 | HTT (0.71) | GABRA1GABRB2HTTALDH1A1HPGD | |
| Zinc Ion SCHEMBL9550437 | 0.78 | HTT (0.57) | GABRA1GABRB2HTTALDH1A1HPGD | |
| SCHEMBL9349415 | 0.78 | HTT (0.57) | GABRA1GABRB2HTTALDH1A1HPGD | |
| SCHEMBL12088394 | 0.77 | GAA (0.59) | GABRA1GABRB2HTTALDH1A1HPGD | |
| SCHEMBL10016276 | 0.76 | JAK2 (0.63) | GABRA1GABRB2HTTALDH1A1HPGD | |
| SCHEMBL10426007 | 0.76 | JAK2 (0.63) | GABRA1GABRB2HTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009072002-A2 | BISPHENOLS IN CANCER THERAPY | UNIVERSITY OF MANITOBA (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300298-A1 | Honokiol Derivates For the Treatment of Proliferative Disorders | CCNK, CDK3, CCNO | GABRA1 4042/4885GABRB2 4180/4885HTT 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.